title: Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?
authors.affiliation: Liver Unit, Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
authors.forename: S E
authors.initials: SE
authors.lastname: Congly
authors.forename: S S
authors.initials: SS
authors.lastname: Lee
mesh_terms: D000998:Antiviral Agents / Q000191:economics*; D019698:Hepatitis C, Chronic / Q000191:economics*; D006801:Humans; D016898:Interferon-alpha / Q000191:economics*; D011092:Polyethylene Glycols / Q000191:economics*; D012254:Ribavirin / Q000191:economics*; D014542:Uridine Monophosphate / Q000031:analogs & derivatives*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011092:Polyethylene Glycols; D012254:Ribavirin; D014542:Uridine Monophosphate